Measurements of CNS-reactive B cells and their specificity in the blood of ocrelizumab-treated patients

Measurements of CNS-reactive B cells and their specificity in the blood of ocrelizumab-treated patients - OcreScreen

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00029110

Enrollment

Registered

2022-05-19

Start date

2022-06-01

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G35

Interventions

Group 1: Measurement of CNS-reactive B cells in the blood of patients with relapsing remitting multiple sclerosis treated with Ocrevus.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: RRMS, Treatment with Ocrevus

Exclusion criteria

Exclusion criteria: Lack of compliance

Design outcomes

Primary

Measure	Time frame
EDSS increase >1 for patients with EDSS from 0,5-5 at study baseline EDSS increase >0,5 for patients with EDSS >5 at baseline	—

Secondary

Measure	Time frame
1) Absolute value of EDSS 2) EDSS change to baseline 3) Time to disease worsening confirmed after 12 weeks 4) Relative change in EDSS at any point during the study compared to previous measurement set in relation to the relative change in CNS-reactive B cells in the blood from previous measurement as measured by B-cell ELISPOT 5) Relative change in EDSS at any point during the study compared to study baseline set in relation to the relative change in CNS-reactive B cells in the blood from previous measurement as measured by B-cell ELISPOT 6) Annualized relapse rate (ARR) 7) Absolute value in 9-hole peg test performance 8) Change in 9-hole peg test performance to baseline 9) Changes in the antibody specificity as measured by proteome array 10) Body mass index	—

Measure

Time frame

1) Absolute value of EDSS 2) EDSS change to baseline 3) Time to disease worsening confirmed after 12 weeks 4) Relative change in EDSS at any point during the study compared to previous measurement set in relation to the relative change in CNS-reactive B cells in the blood from previous measurement as measured by B-cell ELISPOT 5) Relative change in EDSS at any point during the study compared to study baseline set in relation to the relative change in CNS-reactive B cells in the blood from previous measurement as measured by B-cell ELISPOT 6) Annualized relapse rate (ARR) 7) Absolute value in 9-hole peg test performance 8) Change in 9-hole peg test performance to baseline 9) Changes in the antibody specificity as measured by proteome array 10) Body mass index

—

Countries

Germany

Contacts

Public ContactStefanie Kürten

Institut für Neuroanatomie, Universitätsklinikum Bonn

stefanie.kuerten@uni-bonn.de+49 228/ 732642

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 11, 2026